The disappearance of gastric metastasis and liver metastasis in non-small cell lung adenocarcinoma is due to osimertinib.

Abstract

PURPOSE:

Gastric metastasis of lung cancer is rare, and the cases of disappearance of gastric metastasis and liver metastasis caused by oxitinib treatment have not been reported.

METHODS:

A 47-year-old male patient with no history of diabetes, hypertension or smoking presented with chest discomfort after eating. At the time of consultation, the diagnosis of adenocarcinoma of the right lower lobe of the lung with liver and gastric metastasis was considered by pathological examination of biopsy of the fundus of the stomach near the cardia, pathological examination of CT-guided lung aspiration and pathological examination of liver occupancy aspiration, combined with immunohistochemical results. He was found to have exon 19 deletion in next generation sequencing. We performed osimertinib on him (EGFR-TKI) systemic therapy, followed by local radiation therapy to the right lower lung primary lesion.

RESULTS:

After systemic treatment with osimertinib and local radiotherapy of the primary site, the metastases disappeared and the primary site showed post-radiotherapy changes, and the evaluated efficacy was complete remission.

CONCLUSIONS:

This is the first report to our knowledge of a patient who presented with gastric and hepatic metastases from lung cancer and achieved complete remission with osimertinib and local radiotherapy, with good quality of life, which also provides a basis for future clinical work and is of great significance.

• Authors: Yun Wang, Chao Yan, Chuantao Zhang, Enhao Yu, Kai Wang, Xiangyong Liu, Jie Yu, Chunyang Zhou, Aijie Yang
• Journal: Journal of cancer research and clinical oncology (J Cancer Res Clin Oncol) Vol. 149 Issue 17 Pg. 16069-16073 (Nov 2023) ISSN: 1432-1335 [Electronic] Germany
• PMID: 37695388 (Publication Type: Case Reports, Journal Article)
• Copyright: © 2023. The Author(s).

Chemical References

• osimertinib
• ErbB Receptors
• Aniline Compounds
• Protein Kinase Inhibitors

Topics

• Humans
• Male
• Middle Aged
• Quality of Life
• ErbB Receptors (genetics)
• Lung Neoplasms (drug therapy, pathology)
• Adenocarcinoma (drug therapy, pathology)
• Aniline Compounds (therapeutic use)
• Liver Neoplasms (drug therapy, secondary)
• Adenocarcinoma of Lung (drug therapy)
• Lung (pathology)
• Stomach (pathology)
• Mutation
• Protein Kinase Inhibitors (therapeutic use)